Research
Hormonal
GLP-1 RAs reduce blood pressure and albuminuria in patients with CKD and overweight/obesity, contributing to kidney and cardiovascular protection.
GLP-1 RAs can help lower your blood pressure and reduce protein in your urine (albuminuria), which are important markers for kidney and heart health. This benefit is partly due to weight loss but also direct effects of the medication.
GoodSupportsHIGH confidence
Kidney secondary outcomes from CVOTs showed a decrease in albuminuria and in events... integration of results from recent GLP-1 RA and older weight loss drug trials suggest a good correlation between weight loss and a decrease in BP ( R2 = 0.91 for SBP) , a result mainly driven by GLP-1 RAs
Why this rating
Based on secondary outcomes from large CVOTs and meta-analyses.
Source
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Daria Abasheva et al. · Clinical Kidney Journal · 2024
DOI 10.1093/ckj/sfae296
narrative_reviewCited 45×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) provide cardiovascular and kidney protection in patients with chronic kidney disease (CKD) and overweight/obesity, with or without type 2 diabetes (T2DM), by reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression.Strong
- Lifestyle interventions alone are difficult to maintain long-term for weight loss in patients with T2DM and CKD, whereas GLP-1 RAs offer a pharmacological alternative with proven metabolic and organ protection benefits.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →